Reversal of neuromuscular block by sugammadex for peripheral nerve block using combined ultrasound and neurostimulation guidance under general anesthesia

Reversal of neuromuscular block by sugammadex for peripheral nerve block using combined ultrasound and neurostimulation guidance under general anesthesia - Reversal of neuromuscular block for peripheral nerve block under general anesthesia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027916

Enrollment

Registered

2017-06-30

Start date

2017-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who undergo upper or lower extremity surgery under general anesthesia

Interventions

administration of sugammadex (2 mg kg-1) before peripheral nerve block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 yr or older, with ASA physical status I-III, scheduled to receive general anesthesia and nerve blocks for the upper or lower extremity surgery

Exclusion criteria

Exclusion criteria: patients with neuromuscular disease, severe diabetes mellitus, or allergy to local anesthetics, muscle relaxants or sugammadex

Design outcomes

Primary

Measure	Time frame
Efficacy of dual guidance (nerve stimulation) for peripheral nerve block under general anesthesia	—

Secondary

Measure	Time frame
dose of sugammadex in reversing neuromuscular block, the degree of neuromuscular blockade assessed using TOF Watch SX, threshold current in nerve stimulation, adverse events	—

Countries

Japan

Contacts

Public ContactKazuyoshi Aoyama

Kitakyushu General Hospital Department of Anesthesia

kazuyoshi.aoyama@kitakyu-hp.or.jp093-921-0560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026